Peptide Therapy Foundations: Metabolic Balance
Course Details
This course examines the peptides reshaping metabolic medicine: the incretin mimetics and related agents that act on appetite, glucose handling, and body weight. It is written for clinicians who want a working understanding of how each agent engages its receptors, what the trial evidence shows, and how the options differ as the class expands from single-pathway drugs toward multi-receptor designs.
The lessons move along a spectrum of mechanism. Liraglutide and Semaglutide act as GLP-1 receptor agonists. Tirzepatide adds GIP activity for dual agonism, and Retatrutide extends that further into triple GIP, GLP-1, and glucagon receptor activity. Cagrilintide works through the amylin pathway, and Setmelanotide targets the melanocortin 4 receptor for specific genetic forms of obesity. Together they show how receptor selectivity and combination shape the metabolic effect.
Each lesson follows the same clinical lens: what the agent is, how it works, what the evidence shows, and what a practitioner weighs before applying it. The result is a comparative map of the metabolic class that lets you reason about any single agent in the context of its alternatives.
SSRP FACULTY
William Seeds, MD
William Seeds, MD
William Seeds, MD
Before establishing the SSRP Institute, Dr. Seeds served as a board-certified orthopedic surgeon and sports medicine specialist for nearly three decades, including Chief of Surgery, Orthopedic Residency Site Director, and Director of The Ohio Bone & Joint Institute for University Hospitals.
His significant contributions to sports medicine have been recognized at the NFL Hall of Fame. He has consulted for athletes across all major sports leagues, including the NFL, NHL, MLB, NBA, and even the performers on “Dancing with the Stars.”
Through his research at the SSRP Institute, Dr. Seeds continues to explore the cellular pathways and mechanisms that positively impact disease and dysfunction in the body as well as optimize physical performance.
Setmelanotide
In-ProgressLesson Resources
Overview
Setmelanotide, marketed under the trade name Imcivree, is a selective melanocortin-4 receptor (MC4R) agonist developed for rare forms of genetic obesity. It is an eight amino acid cyclic peptide given as a daily subcutaneous injection. The FDA approved it in 2020 for POMC, PCSK1, and leptin receptor deficiencies, and in 2022 it was recognized for Bardet-Biedl syndrome. The indication is chronic weight management in genetically confirmed patients over six years of age, not general obesity.
The clinical relevance here is that these patients previously had no effective pharmacologic option. Diet, exercise, and surgery offer limited long-term impact when the underlying problem is a defect in the leptin-melanocortin signaling system.
How it works
Leptin normally binds its receptor in the hypothalamus, activating POMC neurons. POMC is cleaved by PCSK1 into alpha-melanocyte stimulating hormone (alpha-MSH), which binds the MC4R to drive satiety and energy expenditure. Genetic defects anywhere along this chain, including POMC, PCSK1, the leptin receptor, and others such as SRC1 and SH2B1, impair MC4R signaling.
Setmelanotide replaces alpha-MSH directly at the MC4R, bypassing those upstream genetic problems. It supports appetite suppression, improved insulin resistance, and increased resting energy expenditure by shifting toward beta-oxidation of fat. As a second-generation MC4R agonist, it avoids the heart rate and blood pressure increases tied to sympathetic activation that limited first-generation compounds.
Evidence and clinical considerations
Across registration trials, roughly 80% of patients with POMC deficiency and 45% with leptin receptor deficiency achieved greater than 10% weight loss at one year. In the Bardet-Biedl trial, about 32% of patients reached that threshold. Benefit depends on continued use; stopping the peptide reverses the gains in patients with these genetic conditions.
Hyperpigmentation is the most common adverse effect, reported in the 70% to 80% range, and is reversible on discontinuation. A black box warning covers depression and suicidal ideation, reported around the 10% range. Injection site reactions, nausea, and other gastrointestinal symptoms are frequent in the first month. The peptide is used with caution in severe renal disease and is not recommended for end-stage renal disease.
Key clinical points
- Targeted mechanism: a selective MC4R agonist that replaces alpha-MSH downstream of upstream leptin-melanocortin defects.
- Genetic confirmation required: indicated only for genetically confirmed POMC, PCSK1, leptin receptor deficiency, or Bardet-Biedl syndrome, not general obesity.
- Dosing: subcutaneous, starting near 0.5 mg daily and titrating by 0.5 mg every two weeks, with adults reaching up to 3 mg and pediatric patients usually under 2 mg.
- Monitoring: full-body skin exams for hyperpigmentation and new nevi, psychiatric screening for depression and suicidal ideation, and renal assessment.
- Favorable cardiovascular profile: no notable increase in heart rate or blood pressure, unlike first-generation MC4R agonists.
Questions? Our Provider Care Team is here to help.
We'd love to help you determine the best next steps on your Cellular Medicine journey.
Continue your learning journey
VIEW ALLAging-Associated Decline of Phosphatidylcholine Synthesis is a Malleable Trigger of Natural Mitochondrial Aging
Dr. Seeds explores how age-related decline in phosphatidylcholine synthesis may contribute to mitochondrial aging and why that matters in Cellular Medicine. This discussion connects membrane integrity, mitochondrial function, methylation, and metabolic resilience, while highlighting how this pathway may be more modifiable than we once thought.
1. Managing shingles outbreaks in GLP-1 patient through peptides (0:40)
2. Peptide strategies in suspected ALS (15:56)
3. Improving durability in dementia treatment (25:08)
In this bonus episode from the MM15 Virtual Summit, Dr. Seeds addresses an important question around the use of GLP-1s for metabolic balancing in patients who do not need to lose weight. He shares his perspective on what may be considered microdosing, along with the clinical thought process he uses when determining appropriate dosing in these more nuanced cases.
Additional questions from the MM15 Virtual Summit can be found in our accompanying article here: [insert article link]
Access the full MM15 Course here: Mastermind 15 on Aesthetics
The Limits of Alternative Peptide Delivery
Dr. Seeds reviews oral, sublingual, and transdermal peptide delivery, and explains why subcutaneous injection remains the gold standard for most peptides. (Question Link)
A Deeper Look at the RAAS System
Dr. Seeds uses this Rabbit Holes episode to build on Journal Club Episode 87, revisiting the renin-angiotensin-aldosterone system and its broader role in cellular signaling. The discussion focuses on receptor balance, local tissue effects, and the mechanisms linking RAS disruption to inflammation, fibrosis, and mitochondrial stress.(Article Link)
The Renin–Angiotensin–Aldosterone System (RAAS): Beyond Cardiovascular Regulation
Dr. Seeds unpacks how RAS receptor balance drives inflammation, fibrosis, mitochondrial dysfunction, and tissue remodeling, far beyond its classical role in blood pressure regulation. (Article Link)
1. SSRI tapering resistance, anxiety during weaning (0:40)
2. Progressive multifocal dystonia (13:27)
3. Complex type 2 diabetes case in a lean, athletic patient (28:32)